Kangdu Pharmaceutical

Wuhan Kangdu Pharmaceutical is a biotechnology company headquartered in Wuhan, China, dedicated to the discovery of innovative small molecule drugs. The company specializes in targeting protein-protein interactions (PPIs), which are traditionally considered difficult to drug using conventional methods. Kangdu utilizes a proprietary technology platform to develop Proteolysis-Targeting Chimeras (PROTACs) and other molecular degraders. Their research pipeline primarily addresses unmet needs in oncology, immunology, and inflammatory diseases. Led by a team of experts in chemical biology, the company focuses on translating complex biological insights into therapeutic candidates. Kangdu has successfully secured multiple rounds of venture capital funding to advance its early-stage programs toward clinical development.